SCHEMBL4497765

SCHEMBL4497765

N#Cc1ccc(-c2csc(N3C(=O)OC[C@H]3Cc3ccccc3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.51
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
RECQL P46063 1/20 0.45
KMT2A Q03164 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
IDH1 O75874 12/20 0.43
JAK2 O60674 1/20 0.40
PRKD3 O94806 1/20 0.40
ABL1 P00519 1/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
LCK P06239 1/20 0.40
CDK1 P06493 1/20 0.40
CSF1R P07333 1/20 0.40
LYN P07948 1/20 0.40
RET P07949 1/20 0.40
KIT P10721 1/20 0.40
FGFR1 P11362 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4510990 0.87 IDH1 (0.45) MEN1MAPTKMT2AIDH1EGFR
SCHEMBL4078206 0.86 GAA (0.51) ARMEN1GAAMAPTRECQL
SCHEMBL4079139 0.86 GAA (0.51) ARMEN1GAAMAPTRECQL
SCHEMBL4078937 0.86 AR (0.49) ARMEN1GAAMAPTRECQL
SCHEMBL4078711 0.84 GAA (0.49) ARMEN1GAAMAPTRECQL
SCHEMBL4084108 0.84 GAA (0.49) ARMEN1GAAMAPTRECQL
SCHEMBL4082583 0.84 GAA (0.49) ARMEN1GAAMAPTRECQL
SCHEMBL4508808 0.83 AR (0.47) ARMEN1GAAMAPTRECQL
SCHEMBL4081499 0.83 AR (0.47) ARMEN1GAAMAPTRECQL
SCHEMBL4077593 0.83 AR (0.47) ARMEN1GAAMAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US claimed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US claimed
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR AR 47/4885MEN1 699/4885GAA 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.